Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib followed by cytarabine in children with refractory BRAF V600E-mutant Langerhans cell histiocytosis
ChiCTR2000033423Phase 4Recruiting
- Sponsor
- West China Second University Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vemurafenib and cytarabine in Langerhans cell histiocytosis (LCH), sponsored by West China Second University Hospital. Primary endpoints: Response rate, Progression-free survival and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
vemurafenibcytarabine
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2000033423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033423.